Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes, Am J Cardiol, vol.96, issue.9, pp.1200-1206, 2005. ,
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes, Circulation, vol.114, issue.8, pp.774-782, 2006. ,
DOI : 10.1161/CIRCULATIONAHA.106.612812
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, Eur Heart J, vol.33, issue.20, pp.2569-2619, 2012. ,
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial, The Lancet, vol.373, issue.9665, pp.723-731, 2009. ,
DOI : 10.1016/S0140-6736(09)60441-4
Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel, Am J Cardiol, vol.2012109, issue.2, pp.214-222 ,
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1- year follow-up in patients receiving prasugrel, J Thromb Haemost, vol.2012, issue.10, pp.101999-2005 ,
Prasugrel monitoring and bleeding in real world patients, Am J Cardiol, vol.2013111, issue.1, pp.38-44 ,
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation, vol.123, issue.23, pp.2736-2747, 2011. ,
Thrombolysis in Myocardial Infarction (TIMI) Trial?phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase, J Am Coll Cardiol, vol.11, issue.1, pp.1-11, 1988. ,
Third universal definition of myocardial infarction, Eur Heart J, vol.33, issue.20, pp.2551-2567, 2012. ,
Checking the Cox model with cumulative sums of martingale-based residuals, Biometrika, vol.80, issue.3, pp.557-72, 1993. ,
DOI : 10.1093/biomet/80.3.557
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, pp.2001-2015, 2007. ,
DOI : 10.1056/NEJMoa0706482
Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes, Circulation, vol.110, issue.16, pp.2361-2367, 2004. ,
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis, Circulation, vol.122, issue.21, pp.2131-2141, 2010. ,
DOI : 10.1161/CIRCULATIONAHA.109.927582
Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel, Am J Cardiol, vol.109, issue.2, pp.214-218, 2012. ,
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, ATLAS ACS 2?TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, pp.9-19, 2012. ,
DOI : 10.1056/NEJMoa1112277
Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE), Eur Heart J, vol.24, issue.20, pp.1815-1823, 2003. ,
Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel ? Thrombolysis in Myocardial Infarction, Circulation, vol.38123, issue.23, pp.2681-2689, 2011. ,